CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of William J. Slichenmyer, M.D., Sc.M., to the position of chief medical officer. Dr. Slichenmyer brings 15 years’ experience leading the clinical development of novel cancer therapeutics at biopharmaceutical companies including Pfizer, Bristol-Myers Squibb and Merrimack Pharmaceuticals. In addition, AVEO has appointed Robert C. Young, M.D., president of RCY Medicine and former chancellor of Fox Chase Cancer Center in Philadelphia, PA, to its Board of Directors.
